Fcg receptors (FcgRs), which bind to the Fc regions of antibodies, play an important role in antibody eŠector functions. In humans, there are four types of activating FcgRs: FcgRI, FcgRIIa, FcgRIIIa, and FcgRIIIb. These are expressed on various eŠector cells such as natural killer (NK) cells, neutrophils and macrophages. FcgRIIIa expressed on NK cells is known to play a pivotal role in antibody-dependent cellular cytotoxicity (ADCC) by therapeutic monoclonal antibodies (mAbs). To assess the ADCC activity of mAbs, the killing of target cells is often measured using human peripheral mononuclear blood cells (hPBMCs) or isolated primary NK cells as eŠector cells. These assays can directly assess the cytotoxicity induced by mAbs, but require fresh blood from donors, and are insu‹ciently reproducible due to diŠerences in eŠector cell activity among donors. We developed a cell-based assay using reporter cell lines expressing human FcgR and a nuclear factor of activated T cells (NFAT)-driven luciferase reporter gene (Jurkat/FcgR/NFAT-Luc), which can estimate the activation of various FcgRs by antigen-bound mAbs in vitro, with high reproducibility. The usefulness of this assay was conˆrmed by comparing mAbs activity with diŠerent abilities to activate FcgRs, including Fc-engineered anti-CD20 mAbs and anti-EGFR mAbs with diŠerent IgG subclasses. We also conˆrmed the application of this assay for the characterization of mAbs product-related substances. Our FcgR reporter assay is a promising new tool for the characterization of therapeutic mAbs in various stages of mAbs development. 

